Investıgatıon of Temporomandıbular Dysfunctıon in Patıents Wıth Breast Cancer-Related Lymphedema
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Ankara, Turkey
- Arife Akbulut
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female patients aged 18-75 years who were treated for unilateral breast cancer and developed breast cancer-related LE were included in the study
Exclusion Criteria:
- Patients with general joint diseases affecting the head and neck region that may cause TMD (e.g. rheumatoid arthritis),
- jaw fracture,
- trauma or orthognathic surgery history,
- cervical disc herniation,
- congenital disease,
- facial paralysis,
- patients who have been treated for TMD for the last 3 months and patients who use antidepressant drugs were excluded.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
mild TMD
|
only assesment
|
|
moderate TMD
|
only assesment
|
|
advanced TMD
|
only assesment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
temporomandibular dysfunction
Time Frame: through study completion, an average of 1 year
|
The Clinical Craniomandibular Dysfunction Index (CDI) was used.
CDI consists of five components including limited mandibular normal joint motion (RMJ), pain during mandibular RMJ, pain during TMJ palpation, pain during palpation of masticatory muscles and pain during mandibular function.
3 points can be given for each component as 0, 1 or 5 points and individuals are graded as no TMD (0 points), mild TMD (1-4 points), moderate TMD (5-9 points) and severe TMD (10-25 points) according to the scores received.
|
through study completion, an average of 1 year
|
|
lymhedema
Time Frame: through study completion, an average of 1 year
|
It was determined according to the criteria determined by the International Lymphology Association .
To determine the severity of LE, circumference measurements were taken from both arms at 4 cm intervals.
If the difference between the two extremities was up to 1.5 cm, it was classified as "normal", between 1.5-3 cm as "mild", between 3-5 cm as "moderate" and over 5 cm as "severe" LE
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
pain
Time Frame: through study completion, an average of 1 year
|
The pain was assessed with the Visual Analog Scale (VAS) at rest and activity.
Patients were asked to mark the point that best described their pain on a 10 cm line (0: no pain, 10: unbearable pain).
The pain intensity with activity was assessed during mouth opening, mouth closing and 60 seconds of gum chewing.
Patients were asked to chew gum using both sides for 60 seconds.
At the end of this period, patients evaluated their pain in the TMJ according to the VAS
|
through study completion, an average of 1 year
|
|
posture
Time Frame: through study completion, an average of 1 year
|
Kyphosis and lordosis angles of the patients were measured with Baseline® Digital inclinometer while the patients were standing in a comfortable position.
"Posture Analysis Method with Photography" was used.
|
through study completion, an average of 1 year
|
|
Measurement of range of motion of cervical joints and shoulder joint
Time Frame: through study completion, an average of 1 year
|
The measurements were made with a Baseline® universal goniometer with a plastic 360 degree quadrant.
Flexion, extension, right-left lateral flexion and rotation angles for the cervical region, and flexion, abduction, external and internal rotation ROM angles for the shoulder joint were measured.
The measurements were made in the sitting position for the cervical region and in the supine position for the shoulder.
Each measurement was repeated 3 times and the average values were recorded.
|
through study completion, an average of 1 year
|
|
anxiety-depression
Time Frame: through study completion, an average of 1 year
|
The Turkish version of the Hospital Anxiety and Depression Scale (HAD) was used.
HAD is a 4-point Likert-type scale with a score between 0 and 21, consisting of 14 questions, 7 of which evaluate anxiety and 7 of which evaluate depression.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Musculoskeletal Diseases
- Stomatognathic Diseases
- Muscular Diseases
- Postoperative Complications
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Joint Diseases
- Jaw Diseases
- Skin Diseases
- Breast Diseases
- Lymphatic Diseases
- Mandibular Diseases
- Craniomandibular Disorders
- Myofascial Pain Syndromes
- Breast Cancer Lymphedema
- Breast Neoplasms
- Lymphedema
- Temporomandibular Joint Disorders
- Temporomandibular Joint Dysfunction Syndrome
Other Study ID Numbers
Other Study ID Numbers
- AYBU-AKBULUT-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.